Senseonics Holdings (SENS) Stock Analysis & Winston Score

Senseonics Holdings makes a medical device that helps people with diabetes track their blood sugar levels. Its main product is the Eversense continuous glucose monitor (CGM), which is unique because it is implanted under the skin and can last up to 365 days — far longer than most CGMs that sit on the skin's surface and need to be replaced every week or two. The company sells to people with diabetes and works through healthcare providers and distribution partners, primarily in the United States and parts of Europe. Senseonics earns revenue by selling the implantable sensor and a separate transmitter that sits on the skin and sends data to a smartphone app. The company is small, with a market cap around $300 million, and its long-wear implant design is its main differentiator in a market dominated by larger rivals like Dexcom and Abbott. The biggest risk is that Senseonics continues to burn through cash at a heavy rate, with operating losses far exceeding its revenue, making future financing a critical concern.